Prostate-specific antigen velocity and repeated measures of prostate-specific antigen

Urol Clin North Am. 1997 May;24(2):333-8. doi: 10.1016/s0094-0143(05)70380-3.


Numerous studies evaluating different populations have shown similar findings with respect to repeated PSA measurements and PSAV. First, there is substantial within-individual variability between repeated PSA measures. Second, this variability between PSA measurements precludes the use of a simple change in PSA as a marker for prostate cancer. Third, when one adjusts the changes that occur in PSA over an elapsed time of 1.5 to 2 years (PSAV), less than 5% of men without prostate cancer will have a PSAV of 0.75 ng/mL/ y or greater, and approximately 70% of men with prostate cancer will have a PSAV of 0.75 ng/mL/ y or greater. These data strongly suggest that PSAV is a specific marker for the presence of prostate cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging / metabolism
  • Humans
  • Male
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / diagnosis*
  • Time Factors


  • Prostate-Specific Antigen